Discovery biotherapeutics bioanalysis: Challenges and possible solutions

Bioanalysis

Volumn 4, Issue 9, 2012, Pages 1003-1007

  Clark, Tracey H ^a   King, Lindsay E ^a  

^a PFIZER INC   (United States)

Author keywords

antibody drug conjugates; assay characterization; assay format considerations; biotherapeutics; discovery bioanalysis; ligand binding assays

Indexed keywords

ANTIGEN; ANTIIDIOTYPIC ANTIBODY; DRUG ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ACCURACY; ANALYTICAL RESEARCH; ANTI IDIOTYPE ASSAY; ANTIBODY DETECTION; ANTIBODY DRUG CONJUGATE ASSAY; ANTIGEN CAPTURE ASSAY; ANTIGEN RECOGNITION; AUTOMATION; CONJUGATE; DILUTION; DISCOVERY BIOTHERAPEUTICS BIOANALYSIS; DRUG DETERMINATION; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; IMMUNOGENICITY; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NOTE; PHARMACOKINETICS; PROTEIN STABILITY; QUALITY CONTROL; SAMPLING; STANDARD; STUDY DESIGN; TOTAL DRUG ASSAY;

ANTIBODIES; HUMANS; IMMUNOASSAY;

EID: 84861357411     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.84     Document Type: Note

References (17)

1. Beum PV, Kennedy AD, Taylor RP. Three new assays for rituximab based on its immunological activity or antigenic properties: Analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Meth. 289(1-2), 97-109 (2004).
2. Blasco H, Lalmanach G, Godat E et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J. Immunol. Meth. 325(1-2), 127-139 (2007).
3. Yang J, Ng C, Lowman H et al. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a generic immunoglobulin pharmacokinetic (GRIP) assay. J. Immunol. Meth. 335(1-2), 8-20 (2008).
4. Pendley C, Shankar G. Bioanalytical interferences in immunoassays for antibody biotherapeutics. Bioanalysis 3(7), 703-706 (2011).
5. Stubenrauch K, Wessels U, Lenz H. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates. J. Pharm. Biomed. Anal. 49(4), 1003-1008 (2009).
6. Lee JW, Kelley M, King LE et al. Bioanalytical approaches to quantify 'total' and 'free' therapeutic antibodies and theirtargets: Technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011).
7. Stephan JP, Kozak KR, Wong WL. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 3(6), 677-700 (2011).
8. Stephan JP, Chan P, Lee C et al. Anti- CD22-MCC-DM1 and MC-MMAF conjugates: Impact of assay format on pharmacokinetic parameters determination. Bioconjug. Chem. 19(8), 1673-1683 (2008).
9. Xu K, Liu L, Saad OM et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal. Biochem. 412(1), 56-66 (2011).
10. Shen BQ, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30(2), 184-189 (2012).
11. Li L, Schantza A, Schweglerb M, Shankara G. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet® biolayer interferometry. J. Pharm. Biomed. Anal. 54(2), 286-294 (2011).
12. Staack RF, Stracke JO, Stubenrauch K, Vogel R, Schleypen J, Papadimitriou A. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: What bioanalysts should know about their reagents. Bioanalysis 3(5), 523-534 (2011).
13. Stubenrauch K, Wessels U, Essig U, Vogel R, Schleypen J. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J. Pharm. Biomed. Anal. 52(2), 249-254 (2010).
14. Roman J, Qui J, Dornadula G, Hamuro L, Bakhtiar R, Verch T. Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis. Pharmacol. Toxicol. Meth. 63(3), 227-235 (2011).
15. Findlay JW, Smith WC, Lee JW et al. Validation of immunoassays for bioanalysis: A pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21(6), 1249-1273 (2000).
16. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003).
17. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007